Plus Therapeutics Inc SEC Filings

Plus Therapeutics: Highbridge reports beneficial ownership of warrants exercisable into common stock. The Schedule 13G states 13,157,894 shares of Common Stock are attributable to Highbridge Capital Management, LLC, representing 7.1% of the class based on 171,550,698 shares outstanding as of March 18, 2026. The shares are described as issuable upon exercise of warrants; the filing attributes voting and dispositive powers to the reporting person and names Highbridge Tactical Credit Master Fund, L.P. as a fund holding more than 5%.

PLUS THERAPEUTICS, INC. granted Chief Development Officer Eric Joseph Daniels equity-based compensation. He received stock options covering 20,000 shares of Common Stock at an exercise price of $7.30 per share, expiring on April 19, 2036. One fourth of these options vest on April 20, 2027, with the remaining options vesting in substantially equal monthly installments over the following 36 months.

Daniels was also awarded 20,000 Restricted Stock Units (RSUs), each representing a contingent right to receive one share of Common Stock. One third of the RSUs vest on July 1, 2027, and the remaining RSUs vest ratably over the next eight quarters in substantially equal increments. These awards are compensation grants rather than open-market purchases or sales.

PLUS THERAPEUTICS, INC. executive Eric Joseph Daniels, Chief Development Officer, filed an initial Form 3 reporting his beneficial ownership of company stock. The filing lists one entry for Common Stock and shows 0 shares owned directly following the reported holdings line.

The transaction section contains no purchases, sales, option exercises, or other transfers, indicating there were no reportable transactions in PLUS Therapeutics stock at the time of this initial ownership statement.

Plus Therapeutics, Inc. reports that Nasdaq has confirmed the company has regained compliance with the exchange’s minimum bid price requirement for continued listing on The Nasdaq Capital Market. Nasdaq found that, from April 6 to April 17, 2026, the closing bid price of the company’s common stock was at or above $1.00 per share.

This followed a one-for-twenty-five reverse split of the company’s common stock, which became effective on April 2, 2026. The company issued a press release on April 21, 2026 announcing the compliance confirmation and noting that Nasdaq has advised the matter is now closed.

Plus Therapeutics, Inc. appointed Dr. Eric J. Daniels as Chief Development Officer, effective April 20, 2026. He will oversee development and approval of the company’s pharmaceutical pipeline.

Under his employment agreement, Dr. Daniels will receive a $460,000 base salary, a 40% target bonus, 20,000 stock options and 20,000 restricted stock units, along with severance and partial equity vesting acceleration if he is terminated without cause or resigns for good reason.

Plus Therapeutics reported that the U.S. FDA has granted Orphan Drug Designation to its radiotherapeutic candidate REYOBIQ (rhenium Re186 obisbemeda) for treating pediatric malignant gliomas, a group of rare, aggressive brain tumors with limited options and poor outcomes.

The designation, which also encompasses pediatric ependymoma, offers potential benefits such as seven years of market exclusivity upon approval, tax credits for clinical trial costs, and certain fee exemptions. It builds on prior regulatory and clinical progress for REYOBIQ in leptomeningeal metastases and pediatric brain cancers, where the drug is being studied in multiple ongoing ReSPECT trials.

Plus Therapeutics, Inc. has implemented a 1-for-25 reverse stock split of its common stock to help meet the Nasdaq Capital Market’s minimum $1.00 bid price requirement for continued listing. The split became effective at 12:01 a.m. Eastern time on April 2, 2026.

Every 25 pre-split shares were combined into one share, reducing issued and outstanding common stock from approximately 171,550,698 shares to approximately 6,862,027 shares, with no change to par value or voting rights. No fractional shares will be issued; eligible holders will receive cash in lieu of fractions. Outstanding equity awards and warrants, as well as shares reserved under the equity plan, are being adjusted proportionately. The stock continues to trade on Nasdaq under the symbol PSTV with a new CUSIP number 72941H806.

PLUS THERAPEUTICS Chief Financial Officer Andrew John Hugh MacIntyre Sims acquired shares through RSU vesting. On April 1, 2026, he exercised Restricted Stock Units to receive a total of 67,452 shares of Common Stock in two transactions of 38,323 and 29,129 shares at an exercise price of $0.00 per share.

Following these transactions, his direct holdings of Common Stock increased to 173,913 shares. Footnotes state that each Restricted Stock Unit represents a contingent right to receive one share of Common Stock and that the RSU grants vest in twelve substantially equal quarterly installments beginning on specified dates.

PLUS THERAPEUTICS, INC. Chief Executive Officer Marc H. Hedrick exercised restricted stock units into common shares in a compensation-related transaction. He acquired a total of 361,313 shares of Common Stock on April 1, 2026 through derivative exercises at a per-share price of $0.00.

The filing shows two RSU conversions of 159,681 and 201,632 units, each RSU representing a contingent right to one common share. Following these transactions, Hedrick directly holds 701,100 shares of Common Stock. The transactions involve no open-market purchases or sales and reflect the vesting and settlement of prior equity awards.